Antibacterial peptide 18N1 with alpha-helical structure as well as preparation method and application of antibacterial peptide 18N1
By designing the antimicrobial peptide 18N1 with an α-helical structure, the site configuration of hydrophobic and alkaline amino acids and the synergistic effect of tryptophan, the problem of insufficient bactericidal activity of existing antimicrobial peptides is solved, and a variety of drug-resistant bacteria are achieved Effective inhibition and sterilization are suitable for a variety of applications and reduce production costs through solid phase synthesis methods.
Patent Information
- Application Number
- CN202410923186.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-15
AI Technical Summary
The bactericidal activity of existing natural antibacterial peptides is not high, the production cost is high, and the synthesis is difficult, which limits its use in practical applications, especially for drug-resistant bacteria such as Staphylococcus aureus, Escherichia coli and Candida albicans. Poor inhibition effect.
An antibacterial peptide 18N1 with an α-helical structure was designed to increase the targeting of the peptide by selecting the site configuration of hydrophobic amino acids and basic amino acids, and the synergistic effects of tryptophan and lysine are used to improve the bacterial membrane. and the peptide was prepared by solid phase synthesis method.
It has achieved effective inhibition and bactericidal treatment for Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans. It has strong antibacterial and bactericidal ability and is not easy to develop drug resistance. It is suitable for drugs and feed additives. and disinfectant.
Smart Images

Figure BDA0004937296610000061 
Figure BDA0004937296610000081 
Figure HDA0004937296620000011
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to an alpha-helical antimicrobial peptide 18N1 and a preparation method and application thereof. Background Art
[0002] With the abuse of antibiotics, the drug resistance of many pathogens has been greatly enhanced. More and more drug-resistant bacteria have emerged, becoming a serious problem in the global medical and health community and posing a great threat to human public health. The discovery of antimicrobial peptides has brought new hope to this problem. Natural antimicrobial peptides are small molecule polypeptides with antimicrobial activity produced in the biological defense system and belong to the natural defense system of organisms. Unlike traditional antibiotics that mainly target certain specific intracellular targets of pathogens, most small molecule cationic antimicrobial peptides usually first act on the bacterial cell membrane through electrostatic interactions, and then destroy the cell membrane or interfere with the synthesis of enzymes, proteins, cell walls or nucleic acids to inhibit microorganisms. Therefore, many antimicrobial peptides show broad-spectrum bactericidal activity against Gram-positive bacteria, Gram-negative bacteria and fungi, including some multidrug-resistant bacteria. However, compared with traditional antibiotics, the bactericidal activity of most existing natural antimicrobial peptides is not high, but the production cost is high and the synthesis is difficult, which greatly limits the application of antimicrobial peptides in actual production. Summary of the invention
[0003] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides an antimicrobial peptide that has good antibacterial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans.
[0004] The present invention also provides a method for preparing the antimicrobial peptide.
[0005] The present invention also provides the application of the antimicrobial peptide.
[0006] The invention also provides a product.
[0007] According to one aspect of the present invention, an antimicrobial peptide is provided, wherein the antimicrobial peptide is selected from any one of the following (1)-(2):
[0008] (1) a polypeptide having an amino acid sequence as shown in SEQ ID NO: 1;
[0009] (2) A polypeptide having the same function as the polypeptide shown in (1) obtained by replacing, deleting or adding one or more amino acids at the N-terminus and the C-terminus of the amino acid sequence shown in SEQ ID NO: 1.
[0010] In some embodiments of the present invention, the bacteria include bacteria and fungi.
[0011] In some embodiments of the present invention, the bacteria include Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
[0012] In some embodiments of the invention, the fungus comprises Candida albicans.
[0013] In some embodiments of the present invention, the structure of the antimicrobial peptide is an α-helical structure.
[0014] The polypeptide of the scheme of the present invention selects hydrophobic amino acids, basic amino acids and adjusts and replaces the sites of specific amino acids on the polypeptide helical wheel, so that the hydrophobic amino acids are distributed on one side and the basic amino acids are distributed on the other side in the final helical wheel projection diagram, the hydrophobicity of the polypeptide is adjusted by tryptophan, arginine is added to provide a positive charge targeting the bacterial membrane to improve the antibacterial effect, and the targeting effect of the polypeptide on Candida albicans is improved by the synergistic effect of tryptophan and lysine, and finally the antibacterial peptide sequence of the scheme of the present application is determined.
[0015] According to a second aspect of the present invention, a biomaterial is provided, wherein the biomaterial is any one of 1) to 4):
[0016] 1) A nucleic acid molecule encoding the above antimicrobial peptide;
[0017] 2) An expression cassette containing the nucleic acid molecule described in 1);
[0018] 3) A recombinant vector containing 1) the nucleic acid molecule or 2) the expression cassette;
[0019] 4) A recombinant cell containing 1) the nucleic acid molecule, 2) the expression cassette or 3) the recombinant vector.
[0020] The second aspect of the present invention proposes a method for preparing the above antimicrobial peptide, which comprises the following steps: using a solid phase synthetic resin as a starting material and adopting a solid phase synthesis method to prepare the antimicrobial peptide.
[0021] In some embodiments of the present invention, the antimicrobial peptide can also be artificially synthesized.
[0022] In some embodiments of the present invention, the preparation of the antimicrobial peptides is carried out one by one from the C-terminus to the N-terminus.
[0023] In some embodiments of the present invention, the solid phase synthesis resin comprises Rink resin.
[0024] In some embodiments of the present invention, the method further comprises immersing the solid phase synthetic resin in a DMF solution to make it swell.
[0025] In some embodiments of the present invention, the solid phase synthetic resin is immersed in the DMF solution for 30-50 minutes.
[0026] In some embodiments of the present invention, the solid phase synthesis method includes connecting an amino acid containing a protecting group to a resin, and sequentially performing the steps of washing, deprotection, and coupling until the last amino acid is grafted to obtain a polypeptide chain; the polypeptide chain is sequentially deprotected and washed, and then cut to obtain the antimicrobial peptide.
[0027] In some embodiments of the present invention, the protecting group comprises Fmoc-.
[0028] In some embodiments of the present invention, an amino acid containing a protecting group is attached to a resin, and an activating agent used includes 0.3-0.5 M HBTU and 1-3 M DIEA.
[0029] In some embodiments of the present invention, the reagent used for flushing includes DMF.
[0030] In some embodiments of the present invention, the deprotection comprises the steps of adding 15%-25% by mass of a piperidine deprotection solution, removing the liquid phase after the reaction, and washing the resin.
[0031] In some embodiments of the present invention, the reagent used to clean the resin includes DMF.
[0032] In some embodiments of the present invention, the coupling comprises the step of dissolving the deprotected resin and then adding HBTU and an amino acid mixture to react.
[0033] In some embodiments of the present invention, the concentration of HBTU is 0.3-0.5M.
[0034] In some embodiments of the present invention, the preparation of the amino acid mixture comprises: introducing nitrogen into the amino acid solution to activate the amino acid solution, and then adding a DIEA solution with a concentration of 1-3 M to react.
[0035] In some embodiments of the present invention, the washing liquid used for washing includes at least one of DMF, methanol and dichloromethane.
[0036] In some embodiments of the present invention, the cutting uses a cutting fluid.
[0037] In some embodiments of the present invention, the cutting fluid comprises the following components: TFA, Tis, EDT, thioanisole, and phenol.
[0038] In some embodiments of the present invention, the method further comprises washing the antimicrobial peptide with ether.
[0039] In some embodiments of the present invention, the temperature of the diethyl ether is 0-8°C.
[0040] According to a fourth aspect of the present invention, the use of the above antimicrobial peptides or biomaterials in the preparation of antimicrobial products is proposed.
[0041] In some embodiments of the present invention, the bacteria include bacteria and fungi.
[0042] In some embodiments of the present invention, the bacteria include Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
[0043] In some embodiments of the invention, the fungus comprises Candida albicans.
[0044] In some embodiments of the present invention, the product comprises a medicine, a feed additive, a preservative or a disinfectant.
[0045] According to a fifth aspect of the present invention, a product is provided, comprising the above-mentioned antimicrobial peptide.
[0046] In some embodiments of the present invention, the product comprises a medicine, a feed additive, a preservative or a disinfectant.
[0047] In some embodiments of the present invention, the product has an antibacterial effect.
[0048] In some embodiments of the present invention, the bacteria include bacteria and fungi.
[0049] In some embodiments of the present invention, the bacteria include Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
[0050] In some embodiments of the invention, the fungus comprises Candida albicans.
[0051] In some embodiments of the present invention, the drug further comprises a pharmaceutically acceptable carrier.
[0052] In some embodiments of the present invention, the pharmaceutical carrier is a conventional drug carrier in the pharmaceutical field.
[0053] In some embodiments of the present invention, the pharmaceutical carrier includes at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.
[0054] In some embodiments of the invention, the excipient comprises water.
[0055] In some embodiments of the present invention, the filler comprises at least one of starch and sucrose.
[0056] In some embodiments of the present invention, the binder includes at least one of a cellulose derivative, alginate, gelatin and polyvinyl pyrrolidone.
[0057] In some embodiments of the invention, the humectant comprises glycerin.
[0058] In some embodiments of the present invention, the disintegrant comprises at least one of agar, calcium carbonate and sodium bicarbonate.
[0059] In some embodiments of the invention, the absorption enhancer comprises a quaternary ammonium compound.
[0060] In some embodiments of the invention, the surfactant comprises cetyl alcohol.
[0061] In some embodiments of the present invention, the adsorption carrier includes at least one of kaolin and bentonite.
[0062] In some embodiments of the present invention, the lubricant includes at least one of talc, calcium stearate, magnesium stearate and polyethylene glycol.
[0063] In some embodiments of the present invention, the mass fraction of the antimicrobial peptide in the medicine, feed additive, preservative or disinfectant is 0.01% to 99%.
[0064] According to some preferred embodiments of the present invention, the mass fraction of the antimicrobial peptide in the medicine, feed additive, preservative or disinfectant is 0.05% to 95%.
[0065] According to some preferred embodiments of the present invention, the mass fraction of the antimicrobial peptide in the medicine, feed additive, preservative or disinfectant is 0.05% to 20%.
[0066] In some embodiments of the present invention, the dosage form of the drug is various conventional dosage forms in the art, preferably in the form of solid, semisolid or liquid, and can be an aqueous solution, non-aqueous solution or suspension, more preferably tablets, capsules, soft capsules, granules, pills, oral liquids, dry suspensions, pellets, dry extracts, injections or infusions, transdermal agents, and transdermal microneedles.
[0067] In some embodiments of the present invention, the drug may be administered by any conventional method in the art, including but not limited to injection or oral administration.
[0068] The injection administration can be intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection or subcutaneous injection.
[0069] According to some embodiments of the present invention, at least the following beneficial effects are achieved: the antimicrobial peptides prepared by the scheme of the present invention have strong antibacterial and bactericidal abilities against Pseudomonas aeruginosa by rationally configuring sites of basic amino acids, hydrophobic amino acids, tryptophan, etc., and have obvious inhibitory effects on Escherichia coli, Staphylococcus aureus and Candida albicans. They have the potential to be used as antimicrobial drugs, feed additives, preservatives or disinfectants, and are not prone to drug resistance. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0071] Figure 1 It is a spiral wheel projection diagram of the antimicrobial peptide 18N1 in Example 1 of the present invention;
[0072] Figure 2 is a three-dimensional structure diagram of the antimicrobial peptide 18N1 in Example 1 of the present invention;
[0073] Figure 3 This is a diagram showing the reverse phase high performance liquid chromatography detection results of the antimicrobial peptide 18N1 in Example 1 of the present invention. DETAILED DESCRIPTION
[0074] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0075] Example 1
[0076] This example prepares an antimicrobial peptide 18N1, and the specific process is as follows:
[0077] 1. Design of antimicrobial peptides
[0078] By selecting hydrophobic amino acids (leucine, alanine, phenylalanine), basic amino acids (arginine, lysine) and adjusting and replacing the sites of specific amino acids on the polypeptide helical wheel, the hydrophobicity of the polypeptide was adjusted so that the hydrophobic amino acids on the final helical wheel were distributed on one side and the basic amino acids were distributed on the other side. The antimicrobial peptide 18N1 was finally designed. The sequence and physicochemical parameters are shown in Table 1.
[0079] Table 1 Sequence and physicochemical parameters of antimicrobial peptide 18N1
[0080]
[0081] aThe average hydrophobicity value was calculated by HeliQuest;
[0082] b The hydrophobic moment was calculated by HeliQuest analysis.
[0083] HeliQuest was used to predict the performance and helical wheel projection of peptide 18N1. Figure 1 As shown in Figure 2, lysine and arginine residues are distributed on the same side of the helical wheel projection, and other amino acids are distributed on the other side. The online software PEP-FOLD 3 was used to predict the three-dimensional conformation of the peptide, as shown in Figure 2. Figure 2 As shown, 18N1 exhibits a typical α-helical structure.
[0084] 2. Synthesis of antimicrobial peptides by solid phase chemical synthesis
[0085] The preparation of antimicrobial peptides is carried out one by one from the C-terminus to the N-terminus, and is completed by a peptide synthesizer. The first step is to swell the resin. The Rink resin is immersed in a DMF solution and shaken at a constant speed for 40 minutes to fully swell the resin. Then the first Fmoc-protected amino acid is connected to the resin, and 0.4 moles of HBTU and 2 moles of DIEA are used as activators. The first amino acid is connected, and then the resin is rinsed six times (rinsed with 15mL DMF), deprotected (15mL of 20% piperidine deprotection solution is added to the reaction bottle, and the waste liquid is discharged after 40 minutes of reaction, and the resin is washed six times with 15mL DMF), coupled (0.51g Fmoc-Gly-OH is dissolved in 5mL DMF, 4.3mL of 0.4M HBTU is added thereto, and nitrogen is passed through for 30min to fully mix and activate the amino acid; 1.71mL is added to the amino acid solution After 2M DIEA solution was reacted with nitrogen for 5 minutes, the amino acid mixture was added to the reaction bottle, shaken and nitrogen was introduced for 70 minutes. After each amino acid was grafted, the steps of rinsing the resin six times, deprotection, and coupling were repeated until the last amino acid was grafted. Finally, the resin was deprotected and washed repeatedly with DMF, methanol, and dichloromethane (DMF, methanol, and dichloromethane were used in an amount of 15 mL each time, and each washing took 3 minutes). Then, the polypeptide was cut with a cutting solution (containing 16.3 mL TFA, 0.38 mL Tis, 0.38 mL EDT, 1.38 mL thioanisole, 1.46 g phenol, and 1.46 mL deionized water), and the cold ether was repeatedly precipitated and washed to obtain the initial product.
[0086] Reverse phase high performance liquid chromatography (RP-HPLC) was used to analyze and purify the initial product using a C18 column to obtain the purified polypeptide 18N1, wherein the analytical column used was 5 μm and the preparative column used was 10 μm. Two mobile phases were used in the experiment, wherein phase A contained 99.9% deionized water and 0.1% trifluoroacetic acid, and phase B contained 99.9% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid.
[0087] Reverse phase high performance liquid chromatography of peptide 18N1 Figure 3 The results of reverse phase high performance liquid chromatography showed that the purity of the synthetic peptide was greater than 97%.
[0088] Example 2
[0089] This example measured the antibacterial activity of the antimicrobial peptide 18N1 prepared in Example 1, and the specific process was as follows:
[0090] Determination of minimum inhibitory concentration (MIC):
[0091] Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa were cultured using LB-Broth and LB agar plates, and Candida albicans was cultured using YPD Broth and YPD agar plates. The polypeptide was dissolved in deionized water and then transferred to LB-broth or YPD Broth to obtain a polypeptide stock solution. The polypeptide was then serially diluted in LB-broth / YPD Broth (final concentrations were 6667μg / mL, 3333μg / mL, 1667μg / mL, 833μg / mL, 417μg / mL, 208μg / mL, 104μg / mL, 52μg / mL, 26μg / mL and 13μg / mL, respectively). LB-broth / YPD Broth without polypeptide was prepared as a control. The concentration of the microbial suspension was adjusted to 1-5×10 6 CFU / mL, and add 100 μL of microbial suspension to 11 tubes of peptides of different concentrations. Incubate at 37°C for 24 hours. Observe with the naked eye that the tube with the lowest drug concentration has no bacterial growth and is clear and transparent, which is the MIC of the tested bacteria.
[0092] Determination of minimum bactericidal concentration (MBC):
[0093] After the minimum inhibitory concentration was determined and observed with the naked eye, 0.1 mL of liquid was taken from each dilution tube without bacterial growth and added to a 90 mm LB-agar / YPD agar plate. The plate was evenly spread with a sterile glass rod. The bacterial solution of the control group was diluted 10 5Then 100 μL of the control group bacterial solution was spread on the agar plate like the experimental group. After incubation at 37℃ for 24 hours, the number of colonies on the plate was observed. The lowest drug concentration corresponding to the plate with no more than 5 colonies was the minimum bactericidal concentration of MBC.
[0094] Table 2 Test results of minimum inhibitory concentration and minimum bactericidal concentration of peptide 18N1
[0095]
[0096] The test results of peptide MIC and MBC are shown in Table 2. It can be seen from Table 2 that the designed peptide 18N1 showed obvious inhibitory effects on the four representative bacterial species. Especially for Pseudomonas aeruginosa, its minimum inhibitory concentration value was only 13μg / mL, and the minimum bactericidal concentration was only 52μg / mL. In addition to the common Escherichia coli and Staphylococcus aureus, it also showed good inhibitory and bactericidal effects on the more difficult fungi, Candida albicans.
[0097] Due to the differences in the testing methods for MIC and MBC, the sterilization rate corresponding to the lowest sterilization concentration of the peptide for each bacterial species in the present results is much higher than 99.99%.
[0098] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. An antimicrobial peptide, characterized in that: The antimicrobial peptide is selected from any one of the following (1)-(2): (1) a polypeptide having an amino acid sequence as shown in SEQ ID NO: 1; (2) A polypeptide having the same function as the polypeptide shown in (1) obtained by replacing, deleting or adding one or more amino acids at the N-terminus and the C-terminus of the amino acid sequence shown in SEQ ID NO:
1.
2. Biomaterial, the biomaterial being any one of 1) to 4): 1) A nucleic acid molecule encoding the antimicrobial peptide according to claim 1; 2) An expression cassette containing the nucleic acid molecule described in 1); 3) A recombinant vector containing 1) the nucleic acid molecule or 2) the expression cassette; 4) A recombinant cell containing 1) the nucleic acid molecule, 2) the expression cassette or 3) the recombinant vector.
3. A method for preparing an antimicrobial peptide as claimed in claim 1, characterized in that: The preparation method comprises the following steps: using solid phase synthetic resin as a starting material and adopting a solid phase synthesis method to prepare the antimicrobial peptide.
4. Use of the antimicrobial peptide according to claim 1 or the biomaterial according to claim 2 in the preparation of antimicrobial products.
5. The use according to claim 4, characterized in that: The fungi include bacteria and fungi.
6. The use according to claim 5, characterized in that: The bacteria include Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
7. The use according to claim 5, characterized in that: The fungi include Candida albicans.
8. The use according to claim 4, characterized in that The products include medicines, feed additives, preservatives or disinfectants.
9. A product, characterized in that Comprising the antimicrobial peptide as claimed in claim 1; Preferably, the product includes a medicine, a feed additive, a preservative or a disinfectant; More preferably, the drug further comprises a pharmaceutically acceptable carrier.
10. The product according to claim 9, characterized in that The dosage form of the drug is in the form of solid, semisolid or liquid, and can be an aqueous solution, non-aqueous solution or suspension; Preferably, the dosage form is a tablet, capsule, soft capsule, granule, pill, oral solution, dry suspension, drop pill, dry extract, injection, transdermal agent or transdermal microneedle; And / or, the administration method of the drug includes injection or oral administration.
